Table 1

Characteristics of patients who did and did not experience secondary failure of metformin monotherapy after achieving A1C <7%

Failed metforminDid not fail metforminP
n (%)748 (41.6)1,051 (58.4)
Age at initiation57.7 ± 12.359.2 ± 11.30.008
Diabetes duration (months)26.5 ± 29.6)21.4 ± 28.0<0.001
Last metformin dose1,465 ± 5641,342 ± 573<0.001
A1C before metformin (%)8.2 ± 1.87.9% ± 1.8<0.001
% Male50.047.30.257
% Non-white10.010.20.904
Initial metformin dose (mg)1,073 ± 5021,076 ± 5080.903
BMI (kg/m2)35.7 ± 7.735.6 ± 8.00.842
Systolic blood pressure (mmHg)134 ± 13135 ± 140.129
Diastolic blood pressure (mmHg)79 ± 879 ± 90.823
LDL cholesterol (mg/dl)111 ± 36113 ± 340.319
HDL cholesterol (mg/dl)42 ± 1041 ± 110.443
Triglycerides (mg/dl)256 ± 269241 ± 2440.255
Estimated glomerular filtration rate (ml/min)93 ± 2592 ± 260.262
% With cardiovascular disease13.514.50.564
% With nephropathy0.40.80.309
% With retinopathy0.40.10.222
% with neuropathy5.12.90.020
Medicine possession ratio ≥0.871.566.70.030
Months to failure or end16.9 ± 12.227.6 ± 13.3<0.001
  • Data are means ± SD or percent, unless otherwise indicated.